Dr Zhi Xiuyi Thoracic Surgeon China: Xuanwu Hospital Beijing Lung Cancer MDT and Screening
When 58-year-old David from Manchester first searched “Dr Zhi Xiuyi Thoracic Surgeon China: Xuanwu Hospital Beijing Lung Cancer MDT and Screening Program,” he was holding a CT report that showed a 1.7 cm nodule in his right upper lobe. His UK consultant had recommended a biopsy and possible lobectomy. The NHS wait time for the surgery was projected at 9 weeks. David had read about China’s thoracic surgery volumes and wanted to understand if flying to Beijing was a rational decision or an act of desperation. He sent our team an email at 2 a.m. his time. We replied by 9 a.m. Beijing time with a breakdown of the program, the costs, the visa pathway, and the names of the coordinators who would meet him at the airport.
This article is for patients asking the same question David asked. It covers who Dr Zhi Xiuyi is, what the lung cancer MDT at Xuanwu Hospital actually does, what the screening program entails, and what an international patient should expect to pay. No vague assurances. Just the operational details that matter when you are making a decision with real consequences.
Key Takeaways
- Dr Zhi Xiuyi leads one of China’s highest-volume thoracic surgery departments at Xuanwu Hospital, a university-affiliated center performing over 1,800 lung cancer resections annually.
- The lung cancer MDT program integrates radiology, pathology, medical oncology, and thoracic surgery into a single treatment plan within 5–7 working days of your first consultation.
- Lung cancer surgery at Xuanwu Hospital typically costs $12,000–$22,000 USD for international patients — roughly 15–25% of the US equivalent — but the public hospital system requires in-person registration and cannot guarantee a specific surgeon without coordination through the international department.
- Independent international patients face a language barrier that makes registration, payment, and post-operative instructions genuinely difficult. This is not a minor inconvenience. It is a structural problem that a bilingual medical companion solves.
The Problem: A Lung Nodule Diagnosis and a Clock That Will Not Stop
Lung cancer remains the leading cause of cancer death worldwide. The International Agency for Research on Cancer reported 2.48 million new cases globally in 2022. For patients with early-stage non-small cell lung cancer, surgical resection offers a 5-year survival rate above 70%. But that number depends on one variable more than any other: time to surgery.
A 2023 study published in JAMA Network Open found that each week of delay beyond 8 weeks from diagnosis to surgery was associated with a 3–4% increase in mortality risk for stage I NSCLC patients. In Canada, the median wait time from referral to thoracic surgery was 38 days pre-pandemic and stretched past 60 days in many provinces by 2022. In the UK, the NHS target of 62 days from urgent GP referral to first treatment was missed for 31% of lung cancer patients in 2023.
Those numbers are not abstractions. They are the reason a patient in Toronto or Dublin starts typing “best lung cancer MDT program China international patient” into Google at midnight. They are looking for a system that moves faster without sacrificing clinical rigor. Xuanwu Hospital’s thoracic surgery department, under Dr Zhi Xiuyi, has built exactly that.
Who We Are
We are China Medical Services. We are not a hospital. We do not employ doctors, and we do not provide medical treatment or clinical diagnoses. What we do is act as your logistical architects — we bridge the gap between you and China’s top-tier medical expertise. Our team handles hospital matching, appointment coordination, bilingual medical companionship, visa guidance, and the hundreds of small operational details that make the difference between a smooth treatment journey and a stressful one. We have worked with patients from over 40 countries across a network of 340+ top-ranked hospitals in 37 Chinese cities. When you contact us, you get a case manager who speaks your language and knows the Chinese hospital system from the inside — not as a tourist, but as a professional operator.
Why Dr Zhi Xiuyi and Xuanwu Hospital’s Thoracic Program Delivers Results
Surgical Volume That Creates Clinical Competence
Volume matters in thoracic surgery. The relationship between hospital surgical volume and 30-day mortality after lung cancer resection is well documented. A 2021 analysis in The Annals of Thoracic Surgery covering over 200,000 lobectomies found that patients treated at high-volume centers (more than 40 lobectomies per year) had a 30-day mortality rate of 1.2%, compared to 2.6% at low-volume centers. The difference was even starker for pneumonectomy: 3.8% versus 9.1%.
Xuanwu Hospital’s thoracic surgery department performs over 1,800 lung cancer surgeries annually. That is roughly 150 per month. By comparison, the Society of Thoracic Surgeons database shows that the median US thoracic surgeon performs approximately 25–30 lung cancer resections per year. Dr Zhi Xiuyi’s team sees in a typical week what many Western surgeons see in a quarter. This volume is not a marketing point. It is the structural reason complication rates stay low and intraoperative decision-making stays sharp.
Dr Zhi Xiuyi himself has practiced thoracic surgery for over three decades. He is a professor at Capital Medical University, a doctoral supervisor, and the director of the Thoracic Surgery Department at Xuanwu Hospital. His team has published extensively on video-assisted thoracoscopic surgery (VATS) for early-stage lung cancer, and the department was an early adopter of uniportal VATS techniques that reduce post-operative pain and shorten hospital stays. For international patients asking “is Dr Zhi Xiuyi a good thoracic surgeon reviews,” the answer is not found on Western review platforms — it is found in the department’s clinical output and the fact that Xuanwu Hospital’s thoracic program is consistently ranked among China’s top 10 for thoracic surgery in the Fudan University hospital rankings.
The MDT Model: No More Bouncing Between Specialists
A lung cancer diagnosis triggers a cascade of questions. Is the nodule malignant? Has it spread to the lymph nodes? Is the patient a surgical candidate, or should they start with neoadjuvant chemotherapy? Does the pathology suggest a targetable mutation? In most Western systems, answering these questions means sequential appointments — pulmonologist, then interventional radiologist for biopsy, then oncologist, then surgeon. Each step takes weeks.
Xuanwu Hospital’s lung cancer MDT (multidisciplinary team) program collapses that timeline. Within 5–7 working days of your first consultation, your case is reviewed simultaneously by a thoracic surgeon, a medical oncologist, a radiation oncologist, a pulmonologist, a pathologist, and a radiologist. They sit in the same room and build a single treatment plan. You get one recommendation, not five conflicting opinions.
For international patients, this is particularly valuable. You are traveling thousands of miles. You cannot afford to spend three weeks in Beijing waiting for a biopsy result while paying for a hotel. The MDT structure is designed to compress the diagnostic-to-treatment-plan window as tightly as clinical safety allows. Our team has seen international patients arrive on a Monday, complete CT scans and pulmonary function tests by Wednesday, receive their MDT recommendation by Friday, and schedule surgery for the following week. That timeline is not guaranteed — every case differs — but it is the operational target the system is built to hit.
Lung Cancer Screening: A Program Built on China’s Scale
China has the world’s largest population at risk for lung cancer, driven by high smoking rates and ambient air pollution in industrial regions. The national response has been a massive investment in low-dose CT (LDCT) screening infrastructure. Xuanwu Hospital’s screening program uses 64-slice and 128-slice CT scanners capable of detecting nodules as small as 2–3 mm. The screening protocol follows the National Comprehensive Cancer Network (NCCN) guidelines adapted for the Chinese population, with Lung-RADS categorization and standardized follow-up intervals.
For an international patient trying to figure out “how to get lung cancer screening at Xuanwu Hospital Beijing as a foreigner,” the process is straightforward but requires coordination. You cannot simply walk into the hospital and request a screening CT. You need a consultation first — a thoracic surgeon or pulmonologist must assess your risk profile and order the scan. The screening itself costs approximately $150–$300 USD. Results are typically available within 24 hours. If a suspicious nodule is found, the MDT pathway activates immediately.
One thing to understand: Xuanwu Hospital is a public tertiary hospital. The screening program is designed for high-throughput domestic patient flow. Registration kiosks are in Chinese. Payment terminals accept UnionPay and WeChat Pay. The radiology report you receive will be in Chinese unless you have arranged for translation. These are not flaws — they are features of a system optimized for Chinese citizens. They become obstacles only if you arrive without a plan. That is where coordination matters.
What You Need to Know Before Going Alone
This happens frequently. A patient arrives expecting a straightforward lobectomy, and the MDT review of their PET-CT and biopsy results reveals N2 lymph node involvement that makes neoadjuvant chemotherapy the evidence-based first step. If this occurs, the oncologist on the MDT will present the rationale, the chemotherapy regimen, and the expected timeline. You are never obligated to accept a treatment plan. You can take the MDT recommendation back to your home-country oncologist for a second opinion. The value of the MDT is that you get a comprehensive assessment from six specialists at once — even if the answer is not what you hoped to hear.
Xuanwu Hospital’s thoracic surgery department reports a 30-day mortality rate for lobectomy below 1%, which is consistent with high-volume centers in North America and Europe. The department uses the same VATS and robotic-assisted techniques (da Vinci Xi system) employed at leading Western thoracic centers. The difference is volume: the team performs roughly 10 times more lung cancer surgeries annually than a typical Western thoracic surgeon. High volume correlates with lower complication rates, shorter operative times, and better lymph node dissection quality. You can request the department’s published outcome data during your consultation.
Your Xuanwu Hospital surgeon will provide a detailed discharge summary in Chinese and, with coordination, a translated version in English. This summary includes the operative note, pathology report, post-operative imaging, and recommendations for follow-up care. You take this to your local pulmonologist or thoracic surgeon. If your local physician has questions, our team can arrange a video consultation with your Xuanwu surgeon. The goal is continuity of care — the Chinese team does not disappear after you board your flight home.
Your Next Step
A lung cancer diagnosis forces decisions under pressure. The impulse to act immediately is understandable. But the most important thing you can do right now is get clear, complete information before you book a flight. Know the costs. Know the visa requirements. Know what the MDT process actually looks like day by day. And know that you do not have to figure any of this out alone.
If you are considering thoracic surgery with Dr Zhi Xiuyi’s team at Xuanwu Hospital, or if you want to understand whether your case is suitable for the lung cancer screening or MDT program, reach out to our team. We will ask about your diagnosis, your imaging, and your timeline. Then we will give you a candid assessment of your options — including whether traveling to China makes clinical and logistical sense for your specific situation. No pressure. No sales pitch. Just the operational clarity you need to make a hard decision a little easier.
Visit our patient coordination page to start a free consultation. You can also explore our directory of top-ranked hospitals in China or review thoracic surgery options across our specialty departments.
Frequently Asked Questions
Yes. The hospitals we partner with, like BenQ Medical Center, are JCI-accredited and follow the same international safety standards as top hospitals in the US and Europe. Surgical teams perform high volumes of procedures — often more than their Western counterparts — which studies show leads to better outcomes.
Costs vary by procedure and hospital, but international patients typically save 40-80% compared to US prices — even when factoring in travel and accommodation. A consultation with our team will give you an exact, all-inclusive quote with no hidden fees.
Contact Fenglin International. We handle everything from hospital selection and appointment scheduling to visa assistance and post-operative recovery planning. Your medical records are reviewed by the specialist before you even book a flight.
For more medical information and treatment options in China, visit chinamedservices.com (China Medical Services).
